Page last updated: 2024-12-09

2-(2,5-dioxo-4,4-dipropyl-1-imidazolidinyl)-N-(3-methoxyphenyl)acetamide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

The compound you provided, **2-(2,5-dioxo-4,4-dipropyl-1-imidazolidinyl)-N-(3-methoxyphenyl)acetamide**, is a complex organic molecule with a specific structure. Its importance lies in its potential for **biological activity** and its role in **medicinal chemistry research**.

Here's a breakdown of its components and potential significance:

* **Imidazolidinyl ring:** This ring structure is common in various pharmaceuticals, including anticonvulsants, antivirals, and antifungal agents. Its presence suggests the compound could have a biological effect.
* **Dipropyl groups:** These branched alkyl chains can influence a molecule's solubility, membrane permeability, and interaction with biological targets.
* **Acetamide group:** This functional group often contributes to a molecule's ability to bind to enzymes or other biological receptors.
* **3-Methoxyphenyl group:** This aromatic group can also influence a molecule's interactions with biological systems.

**Why is it important for research?**

This compound could be a **lead compound** in drug discovery research. Lead compounds are molecules that exhibit some desired biological activity and can be further modified and optimized to create more effective and safe drugs.

**Potential research areas:**

* **Antimicrobial activity:** The imidazolidinyl ring is a known scaffold for antimicrobial agents, and this compound's structure could make it a potential candidate for the development of novel antibiotics.
* **Antiviral activity:** Similar to antimicrobial activity, the imidazolidinyl ring has been explored for its potential to inhibit viral replication.
* **Anti-inflammatory activity:** The molecule's structure could contribute to its ability to reduce inflammation, which is a significant target for drug development.
* **Neurological activity:** The presence of an acetamide group and an aromatic ring could suggest potential activity in the nervous system, potentially leading to therapeutic applications for neurological conditions.

**Note:** It's crucial to understand that without further research, the exact biological activity and importance of this compound are unknown. Research needs to be conducted to assess its properties, toxicity, and potential therapeutic value.

Cross-References

ID SourceID
PubMed CID2089356
CHEBI ID116682

Synonyms (16)

Synonym
MLS000058074 ,
smr000067497
CHEBI:116682
MLS002634925
2-(2,5-dioxo-4,4-dipropylimidazolidin-1-yl)-n-(3-methoxyphenyl)acetamide
HMS2331P22
SR-01000056229-1
sr-01000056229
2-(2,5-dioxo-4,4-dipropyl-1-imidazolidinyl)-n-(3-methoxyphenyl)acetamide
bdbm41230
2-[2,5-bis(oxidanylidene)-4,4-dipropyl-imidazolidin-1-yl]-n-(3-methoxyphenyl)ethanamide
2-(2,5-diketo-4,4-dipropyl-imidazolidin-1-yl)-n-(3-methoxyphenyl)acetamide
cid_2089356
Q27200997
Z14041350
AKOS033314130
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
imidazolidine-2,4-dioneAn imidazolidinone with oxo groups at position 2 and 4.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
RNA polymerase beta subunit (EC 2.7.7.6), partialEscherichia coliIC50 (µMol)50.000011.687217.090023.7759AID826
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (13)

Assay IDTitleYearJournalArticle
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (20.00)29.6817
2010's3 (60.00)24.3611
2020's1 (20.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.56

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.56 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.36 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.56)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]